MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.77 Consensus Target Price from Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been assigned a consensus recommendation of “Hold” from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $25.7692.

A number of research analysts have recently commented on MLTX shares. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a research report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 8th. Jefferies Financial Group lowered shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price target for the company. in a research note on Monday, September 29th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 price target (up from $26.00) on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th.

MoonLake Immunotherapeutics Trading Up 0.3%

Shares of MLTX opened at $15.91 on Thursday. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. The firm’s 50-day moving average price is $14.33 and its 200-day moving average price is $28.97. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.79 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period last year, the firm posted ($0.56) EPS. Sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insider Buying and Selling

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the transaction, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the insider owned 72,908 shares of the company’s stock, valued at $1,099,452.64. The trade was a 64.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 402,908 shares of company stock valued at $5,987,162 in the last ninety days. Insiders own 12.05% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Alliancebernstein L.P. raised its position in shares of MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after purchasing an additional 171,932 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in MoonLake Immunotherapeutics in the third quarter worth about $6,922,000. Hood River Capital Management LLC raised its holdings in MoonLake Immunotherapeutics by 1.9% in the second quarter. Hood River Capital Management LLC now owns 675,445 shares of the company’s stock worth $31,881,000 after buying an additional 12,462 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of MoonLake Immunotherapeutics by 175.0% in the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after buying an additional 350,000 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of MoonLake Immunotherapeutics in the third quarter worth approximately $3,257,000. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.